<DOC>
	<DOCNO>NCT02174237</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics , pharmacodynamics single multiple ascend oral dose LNP1892 healthy male female subject</brief_summary>
	<brief_title>A Study Test Safety/Tolerability Increasing Doses LNP1892 Versus Placebo Healthy Male/Female Subjects</brief_title>
	<detailed_description>This first human , Phase 1 study . Primary purpose ass safety , tolerability , pharmacodynamic pharmacokinetic LNP1892 . Study conduct healthy human subject . Pharmacokinetic study subject administration single multiple dos .</detailed_description>
	<criteria>Subjects ; male female ( Group A3 ) , ethnic origin , 18 65 year age ( inclusive ) Subjects body mass index ( BMI ) 18.0 32.0 kg/m2 inclusive Subjects must good health , determine ; medical history , physical examination , vital sign assessment , 12lead electrocardiogram ( ECG ) Clinical laboratory evaluation ( congenital nonhaemolytic hyperbilirubinaemia acceptable ) Subjects give write informed consent participate study abide study restriction Male subject willing , whose partner willing , use appropriate contraception 3 month final dosing occasion . Female subject childbearing potential ; tubal ligation . Subjects donate ; blood 3 month prior screen , plasma 7 day prior screen , platelet 6 week prior screen Subjects ; consume alcohol , cigarette , tobacco significant history alcoholism drug/chemical abuse determine Investigator Subjects use nonprescribed systemic topical medication , herbal remedy , Vitamin supplement , mineral supplement within 7 day first dose administration . Subjects received medication , within 30 day first dose administration , prescribed systemic topical medication within 14 day first dose administration Subjects abnormality heart rate , blood pressure , temperature respiration rate . Subjects ; positive urine drug screen , positive alcohol breath test result screen first admission . Subjects abnormality 12lead ECG . Female subject pregnant lactate Subjects participate clinical study participate clinical study involve administration investigational drug ( new molecular entity ) past 3 month . Subjects significant history drug allergy similar drug excipients . Subjects clinically significant medical history significant allergic condition opinion investigator Subjects clinically significant range PTH serum calcium vitamin D level judge investigator . Subjects current history hypocalcaemia Subjects ; know serum hepatitis , carrier hepatitis B surface antigen ( HBsAg ) carrier hepatitis C antibody , positive result test HIV antibody . Subjects previously take part withdrawn study post first drug administration . Other standard exclusion criterion like Subjects clinically significant disorder significant abnormal laboratory finding , opinion Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Phase 1 , safety , tolerability , PK , PD</keyword>
</DOC>